Literature DB >> 11391237

In vitro analysis of CD40-CD154 and CD28-CD80/86 interactions in the primary T-cell response to allogeneic "nonprofessional" antigen presenting cells.

J C Laning1, J E Deluca, C M Isaacs And, J Hardin-Young.   

Abstract

BACKGROUND: Recently, several ligand interactions have been examined in detail as potential mediators of costimulatory signaling. The CD154/CD40 and CD28/B7 interactions have been highlighted as being among the more-significant contributors to proper activation of unprimed T lymphocytes. Human keratinocytes (HK) and human dermal fibroblasts (HF) are capable of expressing Class II HLA and CD40 antigens after interferon-gamma exposure, yet neither express significant levels of B7. HK and HF have been characterized as "nonprofessional" antigen presenting cells (APC) and their poor APC function has been partially attributed to deficient costimulatory activity.
METHODS: In this study, we examined whether substituting for costimulatory signaling events through the addition of cross-linked monoclonal antibodies against the T-cell ligand/s (CD28 and/or CD154) could restore allostimulation. Mixed lymphocyte reactions were performed combining enriched human peripheral blood T cells and allogeneic HK or HF with or without stimulatory anti-CD28 and/or anti-CD154 antibodies.
RESULTS: The results show that the addition of anti-CD28 alone permitted HF but not HK to present alloantigen effectively. In contrast, addition of both anti-CD154 and anti-CD28 was required to generate even a moderate proliferative response to allogeneic HK. Further, adding a monomorphic anti-HLA-DR antibody substantially inhibited these responses. Additional experiments suggest that signaling through CD40/CD154 directs HK to produce TGF-beta, which would adversely affect T-cell activation.
CONCLUSIONS: The data presented highlight significant differences in signaling capacities for HK versus HF and provide evidence for a partial mechanism by which allogeneic human skin equivalents might be immunologically null upon engraftment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391237     DOI: 10.1097/00007890-200105270-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Further study of anti-ICOS immunotherapy for rat cardiac allograft rejection.

Authors:  Xuan-Chao Pan; Lei Guo; Ying-Bing Deng; Katsutoshi Naruse; Hiromitsu Kimura; Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  Surg Today       Date:  2008-08-28       Impact factor: 2.549

Review 2.  Mesenchymal cells of the intestinal lamina propria.

Authors:  D W Powell; I V Pinchuk; J I Saada; Xin Chen; R C Mifflin
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

3.  StrataGraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: results from a prospective, randomized, controlled dose escalation trial.

Authors:  John M Centanni; Joely A Straseski; April Wicks; Jacquelyn A Hank; Cathy A Rasmussen; Mary A Lokuta; Michael J Schurr; Kevin N Foster; Lee D Faucher; Daniel M Caruso; Allen R Comer; B Lynn Allen-Hoffmann
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

Review 4.  Coherent somatic mutation in autoimmune disease.

Authors:  Kenneth Andrew Ross
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.